Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's
disease are needed to facilitate the initial screening process of participants in disease …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Alzheimer's disease (AD), is a progressive neurodegenerative disease that affects behavior,
thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …